2H51 Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ocugen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.90 |
| 52 Week High | US$1.92 |
| 52 Week Low | US$0.33 |
| Beta | 3.77 |
| 11 Month Change | -0.17% |
| 3 Month Change | -22.78% |
| 1 Year Change | 158.07% |
| 33 Year Change | -83.76% |
| 5 Year Change | n/a |
| Change since IPO | -51.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2H51 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 11.5% | -0.2% | 0.8% |
| 1Y | 158.1% | -16.9% | 9.1% |
Return vs Industry: 2H51 exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 2H51 exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 2H51 volatility | |
|---|---|
| 2H51 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2H51's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2H51's weekly volatility has decreased from 19% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 65 | Shankar Musunuri | www.ocugen.com |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult.
Ocugen, Inc. Fundamentals Summary
| 2H51 fundamental statistics | |
|---|---|
| Market cap | €256.30m |
| Earnings (TTM) | -€48.79m |
| Revenue (TTM) | €4.48m |
57.2x
P/S Ratio-5.3x
P/E RatioIs 2H51 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2H51 income statement (TTM) | |
|---|---|
| Revenue | US$4.70m |
| Cost of Revenue | US$31.62m |
| Gross Profit | -US$26.91m |
| Other Expenses | US$24.23m |
| Earnings | -US$51.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | -572.66% |
| Net Profit Margin | -1,088.17% |
| Debt/Equity Ratio | 7.1% |
How did 2H51 perform over the long term?
See historical performance and comparison